Key Oncologics
Key Oncologics is a Johannesburg-based, privately held specialty pharmaceutical company founded in 1995 that supplies oncology and hematology medicines and support services to healthcare providers and patients in South Africa's cancer care market.
- Company typePrivate
- Founded1995
- HeadquartersJohannesburg, South Africa
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Key Oncologics does
Key Oncologics is a South African specialty pharmaceutical company headquartered in Johannesburg that focuses on cancer treatment through the supply of pharmaceutical products and related support services in the oncology and hematology therapeutic areas. Founded in 1995, the company operates as a privately held for-profit entity with an estimated 11 to 50 employees, positioning it as a focused niche player rather than a broad-line pharmaceutical manufacturer or distributor. Its website domain is registered (keyoncologics.co.za), supporting a domestic South African footprint, though specific geographic reach beyond South Africa is not disclosed in the available sources.
The company's offering spans pharmaceutical products used in oncology and hematology treatment alongside support services, targeting healthcare providers (oncologists, hematologists, hospital pharmacies, treatment centers) and ultimately patients requiring cancer therapy in South Africa. The precise product portfolio — whether branded originator oncology drugs, generics, biosimilars, cytotoxic agents, supportive care medicines, or a combination — and the underlying sourcing, licensing, and distribution mechanics are not disclosed in the available source material; the company's public website currently renders only a verification/loading screen, and no product catalog, pricing schedules, registration listings, or distribution agreements are publicly indexed. This limits granular assessment of portfolio depth, therapeutic coverage, regulatory standing, and pipeline. No manufacturing capability, clinical research activity, or proprietary technology stack is described.
Given 29 years of continuous operating history, Key Oncologics has demonstrated durability in a regulated, high-barrier therapeutic segment, although the absence of disclosed funding events, partnerships, product launches, or headcount trends prevents assessment of recent strategic momentum, capital structure, or growth trajectory. The company is led by Magriet De Wet in the combined Managing Director and Chief Executive Officer role, consistent with a closely held, owner-led governance structure typical of South African specialty pharmaceutical firms of this size.
Key Oncologics firmographics
Firmographics- Name
- Key Oncologics
- Website
- https://keyoncologics.co.za
- Company type
- Private
- Founded year
- 1995
- Headcount range
- 11–50 employees
- Short description
- Key Oncologics is a Johannesburg-based, privately held specialty pharmaceutical company founded in 1995 that supplies oncology and hematology medicines and support services to healthcare providers and patients in South Africa's cancer care market.
- Ownership category
- akta.pro rank
Key Oncologics industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Medical Oncology (HLAKAFAB)
Keywords
Where Key Oncologics is headquartered
LocationHeadquarters
- HQ city
- Johannesburg
- HQ country
- South Africa
- HQ region
- Africa
Markets served
Key Oncologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales
Key Oncologics product offering
Product offeringCore offering
Key Oncologics supplies pharmaceutical products for cancer treatment, with a focused portfolio in oncology and hematology therapeutic areas. The company complements its pharmaceutical offerings with support services aimed at healthcare providers involved in cancer care across South Africa.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology pharmaceutical products
Companies that use Key Oncologics
Customer profileIdeal customer profiles1 record
Key Oncologics technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Key Oncologics partnerships and signals
Strategic signalRecent moves2 records
Key Oncologics competitors and assessment
Company assessmentRegional players
- Aspen Pharmacare Holdings: Largest South African-based pharmaceutical manufacturer and distributor with oncology and specialty pharma exposure across Africa. Comparable because both are South Africa-anchored pharma companies distributing oncology and specialty medicines into the same regional channels and tenders.
- Adcock Ingram Holdings: Major South African pharmaceutical company with a portfolio that includes specialty and oncology-relevant prescription products. Comparable as another Johannesburg-headquartered pharma distributor serving South African prescribers and institutions with prescription drugs.
- Cipla (South Africa): Major Indian-origin pharmaceutical company with a substantial South African oncology and specialty presence, including hematology oncology products. Comparable because it sells oncology/hematology medicines into the same South African market, often with a focus on affordability.
Broad incumbents
- Roche: Global leader in oncology and hematology pharmaceuticals with an established South African commercial presence. Comparable because it competes with Key Oncologics for the same South African oncology/hematology prescribers and tender slots, though from a vastly larger global portfolio.
- Novartis: One of the world's largest oncology and hematology pharmaceutical companies, with active marketing of branded cancer therapies in South Africa. Directly comparable therapeutic categories (oncology and hematology) and overlap on the same South African prescriber base.
- AstraZeneca: Global biopharmaceutical company with a significant oncology and hematology portfolio and a South African oncology commercial team. Comparable as a competitor for oncologist prescriptions and institutional formulary access in South Africa.
- Pfizer: Multinational pharmaceutical company with a deep oncology/hematology franchise and established South African distribution. Comparable as a competing supplier to the same regional oncology market, although with a much broader product set.
- MSD (Merck & Co.): Global oncology and hematology innovator with Keytruda and other widely used oncology brands distributed in South Africa. Comparable as a competing multinational supplier in the same therapeutic categories and regional market.
- Dr. Reddy's Laboratories: Global pharmaceutical company with an expanding oncology portfolio and active distribution across emerging markets including South Africa. Comparable as a competitor supplying oncology therapies to the same regional channels.
Emerging players
- Specialised Therapeutics Australia: Smaller specialty pharmaceutical company focused on in-licensing and distributing oncology and hematology products in regional markets. Comparable business model to Key Oncologics as a specialist distributor of oncology/hematology medicines in a defined geographic footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Key Oncologics social profiles
Digital presenceKey Oncologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Key Oncologics leadership team
Management profileNumber of profiles
Profiles1 record
Key Oncologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Key Oncologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Key Oncologics
What does Key Oncologics do?
Key Oncologics supplies pharmaceutical products for cancer treatment, with a focused portfolio in oncology and hematology therapeutic areas. The company complements its pharmaceutical offerings with support services aimed at healthcare providers involved in cancer care across South Africa.
When was Key Oncologics founded?
Key Oncologics was founded in 1995. It employs 11 to 50 people.
Where is Key Oncologics based?
Key Oncologics is headquartered in Johannesburg, South Africa, in the Africa region.
Who are Key Oncologics's main competitors?
Regional players on record are Aspen Pharmacare Holdings, Adcock Ingram Holdings and Cipla (South Africa). Broad incumbents are Roche, Novartis, AstraZeneca, Pfizer, MSD (Merck & Co.) and Dr. Reddy's Laboratories. Specialised Therapeutics Australia is listed as an emerging player.
Does Key Oncologics have an API?
No public API is recorded for Key Oncologics.
What industry is Key Oncologics in?
Key Oncologics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.